MindWalk Holdings (HYFT) Interest Expenses (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Interest Expenses of -$83.2 million for Q2 2026, down 136.64% year-over-year from $227.0 million in Q2 2025, and down 136.64% quarter-over-quarter from $227.0 million in Q2 2025.
MindWalk Holdings (HYFT) Interest Expenses (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Interest Expenses for 7 consecutive years, with -$83.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Expenses fell 136.64% year-over-year to -$83.2 million; the TTM figure through Apr 2026 stood at -$83.2 million (down 136.64% YoY), while the FY2026 annual figure was $335572.8, down 99.95% from the prior year.
- Interest Expenses fell to -$83.2 million in Q2 2026 per HYFT's latest filing, from $227.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $227.0 million in Q2 2025 and bottomed at -$83.2 million in Q2 2026.
- Historically, Interest Expenses has averaged $18.2 million across 5 years, with a median of $247217.6 in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 181549.06% — and 2026, when it plunged 136.64%.
- MindWalk Holdings' Interest Expenses stood at $197952.0 in 2022, then jumped by 178.52% to $551330.7 in 2023, then sank by 46.22% to $296483.2 in 2024, then soared by 76457.93% to $227.0 million in 2025, then slumped by 136.64% to -$83.2 million in 2026.
- Business Quant data shows HYFT's Interest Expenses at -$83.2 million in Q2 2026, $227.0 million in Q2 2025, and $296483.2 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -83.16 Mn |
| Apr 30, 2026 | -83.16 Mn |
| Apr 30, 2025 | 226.98 Mn |
| Apr 30, 2025 | 226.98 Mn |
| Apr 30, 2024 | 296,483.15 |
| Apr 30, 2024 | 296,483.15 |
| Apr 30, 2023 | 551,330.69 |
| Apr 30, 2023 | 551,330.69 |
| Oct 31, 2022 | 197,952.02 |
| Oct 31, 2022 | 197,952.02 |
| Jul 31, 2022 | 61.42 |
| Jul 31, 2022 | 61.42 |
| Apr 30, 2022 | 772,974.48 |
| Apr 30, 2022 | 772,974.48 |
| Jan 31, 2022 | 75.85 |
| Jan 31, 2022 | 75.85 |
| Oct 31, 2021 | 108.97 |
| Oct 31, 2021 | 108.97 |
| Jul 31, 2021 | 64,304.66 |
| Jul 31, 2021 | 64,304.66 |